首页> 外文期刊>Molecular and Cellular Biochemistry: An International Journal for Chemical Biology >Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells
【24h】

Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells

机译:Hs578T三阴性乳腺癌细胞中响应阿霉素处理的干细胞相关信号通路的调控

获取原文
获取原文并翻译 | 示例
           

摘要

Different molecular changes have been previously associated with therapeutic response and recurrent disease, however, the detailed mechanism of action in triple-negative breast cancer subtype remains elusive. In this study, we investigated the cellular and molecular signaling of two claudin-low triple-negative breast cancer cells to doxorubicin and docetaxel treatment. Whole human transcriptomic evaluation was used to identify the subsequent changes in gene expression, while biological effects were measured by means of proliferation and anchorage-independent growth assays. Microarray analysis revealed changes in stem cell-related signaling pathways, suggesting that doxorubicin treatment affects the balance between self-renewal and differentiation. While the treatment reduced the proliferation, aggregation and mammosphere forming ability of stem-like cells derived from Hs578T cell line, stem-like cells derived from MDA-MB-231 cells were not significantly affected. Our results suggest that claudin-low triple-negative breast cancer cells might predominantly alter stem cell-related signaling pathways to promote stem-like cells activity as an innate resistance mechanism to doxorubicin treatment.
机译:先前已将不同的分子变化与治疗反应和复发性疾病相关联,但是,三阴性乳腺癌亚型的详细作用机制仍然难以捉摸。在这项研究中,我们调查了两个claudin低三阴性乳腺癌细胞对阿霉素和多西他赛治疗的细胞和分子信号传导。整个人类转录组评估用于确定基因表达的后续变化,同时通过增殖和锚定非依赖性生长测定法测量生物学效应。微阵列分析揭示了干细胞相关信号通路的变化,表明阿霉素治疗影响自我更新和分化之间的平衡。尽管该处理降低了源自Hs578T细胞系的干样细胞的增殖,聚集和形成乳球的能力,但是源自MDA-MB-231细胞的干样细胞并未受到显着影响。我们的结果表明,claudin低的三阴性乳腺癌细胞可能主要改变干细胞相关的信号传导途径,从而促进干细胞样细胞的活性,作为对阿霉素治疗的先天性耐药机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号